Dr. Nihar Desai and I discuss how practice is moving toward
We talk about the importance of MDs reviewing AI output and the timing of CT reassessment of risk Sponsored by […]
Clinical Trial Results
Search
Dr. Ola Akinboboye and Dr. C. Michael Gibson discuss his recent publication showing that acoramidis has similar efficacy in wild-type and variant transthyretin amyloid cardiomyopathy
Sponsored by an independent educational grant from BridgeBio Pharma Inc.
Dr. Nick Nurmohamed and Dr. C. Michael Gibson discuss the new concept of Staging Atherosclerosis, where the type (high risk fatty) and the extent of both obstructive and non-obstructive atherosclerosis in the coronary wall is classified as 0-4 (rather than just saying narrowing’s are present) and how this improves risk stratification.
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Brittany Weber and Dr. C. Michael Gibson discuss: Why Atherosclerosis is All That Really Matters: A Summary for Seamless Integration into Daily Clinical Practice
Sponsored by Cleerly, Women as One and International Atherosclerosis Society.
Dr. Mike Sharma and Dr. C. Michael Gibson discuss the results of the phase III OCEANIC-STROKE Trial
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]
Dr. Roxana Mehran and Dr. C. Michael Gibson discuss: Unmet Needs in Coronary Atherosclerosis: A Discussion of Clinical Trial Designs for Evaluation of Asymptomatic and Symptomatic Patients
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Karim Al-Azizi and Dr. C. Michael Gibson discuss: Caveat Emptor: Advantages and Disadvantages of Current Generation Tools for Evaluation of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society